Pharma Stocks Defy Market Gloom, Nifty Pharma Index Rises Over 1% Led by Glenmark and Mankind
By Shishta Dutta | Published at: Jul 11, 2025 11:09 AM IST
Mumbai, 11 July 2025: In contrast to the broader market’s decline, the Nifty Pharma Index registered a strong gain of 1.01% or 223.15 points, reaching 22,299.95 by 10:15 IST on Friday. The rally was primarily fuelled by robust performances from Glenmark Pharmaceuticals and Mankind Pharma, signalling strong investor interest in selective healthcare counters.
Pharma Outshines Market Even as Nifty 50 Slips
While the Nifty 50 fell by 0.4%, the pharma sector defied the downtrend, supported by defensive buying and company-specific developments. The strong sectoral move highlights the market’s renewed appetite for pharmaceutical stocks amid global healthcare tailwinds and resilient domestic demand.
Key Index Metrics Show Solid Intra-Day Momentum
| Metric | Value |
|---|---|
| Last Price | 22,299.95 |
| Opening Level | 22,172.90 |
| Day’s High | 22,346.80 |
| Day’s Low | 22,157.50 |
| Previous Close | 22,076.80 |
| Change (%) | +1.01% |
| Total Traded Volume | 45.5 lakh |
| Total Traded Value | ₹726.14 crore |
| 52-Week High | 23,907.90 |
| 52-Week Low | 19,121.10 |
| 1-Year Return | +6.52% |
With 17 of the 20 index constituents advancing, the pharma sector showed broad-based strength, a sign of sustained institutional accumulation.
Glenmark’s AbbVie Deal Triggers Sharp Rally
Glenmark Pharmaceuticals emerged as the session’s top gainer, soaring 10% to a new 52-week high of ₹2,094.40. The rally came on the back of its licensing agreement with US-based AbbVie, which gives the global pharmaceutical giant rights to co-develop and commercialise Glenmark’s respiratory drug candidate. The deal sparked investor optimism over future royalty flows and global market access, sharply lifting the stock.
Mankind Pharma Maintains Uptrend with 5% Gain
Mankind Pharma surged 5.11% to ₹2,674.00, building on a consistent upward trend over the past month. The stock has gained over 7% in the last 30 days, with analysts attributing the rally to consistent quarterly results, product launches, and improved margin visibility.
Midcap Pharma Stocks Show Renewed Strength
Other prominent gainers include:
| Change (%) | Near 52W High (%) | ||
|---|---|---|---|
| Gland Pharma | 1,874.60 | +1.65% | -15.6% |
| Ajanta Pharma | 2,627.30 | +1.39% | -24.6% |
| Alkem Laboratories | 4,797.00 | +1.36% | -25.5% |
| Biocon | 376.90 | +1.21% | -6.8% |
| Divi’s Labs | 6,889.00 | +0.65% | -2.6% |
| Sun Pharma | 1,677.00 | +0.87% | -14.5% |
Laurus Labs was particularly notable, trading at ₹794.10-just 0.73% shy of its 52-week high, reflecting strong momentum in niche formulations and CRAMS-related contracts.
Few Decliners Amid Broader Gains
Only three constituents saw mild declines:
| Company | Last Price (₹) | Change (%) | Remarks |
|---|---|---|---|
| Natco Pharma | 983.10 | -1.52% | Profit booking seen |
| Lupin | 1,887.00 | -0.41% | Weak follow-through |
| Granules India | 473.70 | -0.02% | Flat on low volume |
Strong 1-Year and Monthly Returns Highlight Sector Resilience1-Year Index Return: +6.52%
Top 1-Year Gainers:
- Laurus Labs: +67.83%
- Divi’s Laboratories: +47.61%
- Glenmark Pharma: +37.99%
Top 30-Day Movers:
- Laurus Labs: +19.06%
- Glenmark Pharma: +17.85%
- Natco Pharma: +13.23%
What’s Driving the Pharma Rally?
The current momentum in pharma stocks is driven by a combination of global healthcare demand stability, fresh licensing deals, and renewed foreign institutional interest. With rising concerns over valuations in other sectors, investors are gravitating towards pharma due to its defensiveness and growth clarity.
Technical Outlook: Index Nearing 52-Week Peak
The Nifty Pharma Index is now just 6.72% below its 52-week high. Technical analysts suggest that sustained accumulation in stocks such as Divi’s, Glenmark, and Laurus could push the index towards fresh highs in the short term.
Index Overview: A Barometer of Healthcare Sentiment
The Nifty Pharma Index represents India’s leading pharmaceutical firms listed on the NSE. With a mix of large-cap stalwarts and agile mid-cap innovators, the index reflects investor sentiment in healthcare, R&D pipelines, and global pharmaceutical trends. As valuations remain reasonable and growth visibility improves, the sector may continue to attract steady inflows.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
